History of Present Illness:
The patient presented to the emergency department with a 5-day history of worsening abdominal pain, nausea, and vomiting. She had a multiyear history of gastrointestinal discomfort, but no formal workup or endoscopy to date. The patient also stated that she had a thyroid disorder, although she had not previously been treated for thyroid disease. She stated that she had been taking multiple vitamin supplements, including vitamins A, B, and D, as well as a calcium-containing zeolite supplement. Case Studies primary hyperparathyroidism as a cause of hypercalcemia in our patient. 3 Humoral hypercalcemia of malignancy was also less likely due to decreased parathyroid hormone related peptide (PTHrP). Elevated serum PTHrP is observed in 50%-90% of patients with hypercalcemia of malignancy. 4 While a complete skeletal survey was not conducted, osteolytic tumors were not believed to be the cause of our patient's hypercalcemia because bone structures observed on abdominal and pelvic CT were unremarkable. Furthermore, multiple myeloma was unlikely due to normal serum and urine protein electrophoresis. Familial hypocalciuric hypercalcemia (while relatively rare) was not definitively excluded as a possible cause of our patient's hypercalcemia; a 24-hour urine specimen to measure urinary calcium was not collected during her hospitalization. The diagnosis of hypocalciuric hypercalcemia was not pursued given the patient's markedly elevated 25(OH)D levels along with her reported history of vitamin D ingestion. Vitamin D toxicity, however, can certainly be coincident with other clinical disorders. Other possible causes for hypercalcemia can be related to medications and/or dietary supplements such as 1,25(OH) 2 D and calcium therapy for chronic renal disease, use of thiazide diuretics, milk-alkali syndrome, lithium therapy, vitamin A over-consumption, or a combination of these. 1, 2 In this patient, hypercalcemia was most likely due to overconsumption of vitamin D, with an additional contribution possible from calcium-containing zeolite supplements. Laboratory findings did not support her reported intake of vitamin A or vitamin B (at least B 1 ) containing supplements. Other forms of vitamin B were not tested. 4. Vitamin D toxicity is associated with hypercalcemia, nausea, vomiting, weakness, fatigue, hyporeflexia, dehydration, renal failure, and sometimes progresses to tissue calcification. 9, 10 Severe hypercalcemia can be life threatening. Treatment of vitamin D toxicity includes rehydration, cessation of vitamin D supplementation, and restriction of dietary calcium; more severe cases may require the use of glucocorticoids and bisphosphonates to normalize the plasma calcium concentration.
9,10 Gastric irrigation may be indicated in acute cases of vitamin D-containing rodenticide ingestion. 6. Zeolites are adsorbent aluminosilicate minerals with ion-exchange properties that are used in a wide variety of manufacturing processes and domestic products, such as laundry detergent, animal feed, pet litter, and water purification systems. 17 Zeolite-containing capsules, powders, and liquids are widely available online and through health food suppliers, where they are often marketed for their purported "detoxifying" benefits. Some of these supplements are formulated to contain calcium or other vitamins and minerals. Although the dose, duration, and formulation of zeolite supplements were not well documented in our patient, it is possible that the complex electrolyte abnormalities, abdominal symptoms, or both may have been exacerbated by zeolite ingestion.
Patient Follow-Up
The patient's hypercalcemia was corrected with rehydration and administration of zoledronic acid and calcitonin. Rehydration also improved her other electrolyte abnormalities and abdominal symptoms. She was returned to a solid food diet when the concern over a small bowel obstruction diminished. The patient was discharged after resolution of symptoms and correction of her hypercalcemia. Further workup of her reported history of thyroid disease (and mildly elevated thyroid stimulating hormone upon presentation) was deferred to outpatient follow-up. LM
